Medical Use
FILSPARI is a dual antagonist for endothelin and angiotensin II receptors, prescribed to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression. This typically includes patients with a urine protein-to-creatinine ratio (UPCR) of ≥1.5 g/g. It’s important to note that this indication is granted under accelerated approval based on the reduction of proteinuria, and it has not yet been confirmed whether FILSPARI slows the decline in kidney function in IgAN patients. Continued approval may depend on the results of a confirmatory clinical trial.
Dosage and Administration:
- -Before Starting: Discontinue any renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists (ERAs), or aliskiren.
- -Initial Dose: Start with 200 mg orally once daily.
- -After 14 Days: Increase to the recommended dose of 400 mg once daily, as tolerated.
- -Resuming Treatment: If treatment is interrupted, consider starting again with 200 mg once daily and increasing to 400 mg once daily after 14 days.
- -Administration: Instruct patients to swallow the tablets whole with water before their morning or evening meal.
Warning & Precautions
-
Hepatotoxicity: If patients show symptoms of hepatotoxicity, they should stop taking FILSPARI. Treatment should be paused if aminotransferase levels are abnormal and only resumed once levels normalize and symptoms disappear.
Embryo-Fetal Toxicity: FILSPARI can cause harm to a fetus, so it is contraindicated during pregnancy. Patients of childbearing potential must undergo pregnancy tests and use effective contraception.
FILSPARI REMS: Due to the risks of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program. Prescribers must be certified, patients must enroll in the program, and ongoing monitoring is required.
Hypotension: Some patients may experience low blood pressure. Adjustments to other antihypertensive medications and volume status may be necessary, with possible dose reduction or interruption of FILSPARI.
Acute Kidney Injury: Kidney function should be monitored, especially in patients dependent on the renin-angiotensin system.
Hyperkalemia: Regular monitoring of serum potassium levels is important, particularly for high-risk patients.
Fluid Retention: Significant fluid retention should be evaluated, and adjustments to diuretics or FILSPARI dosage may be needed.
Documentation Availability
Documents required to import Filspare (sparsentan)to India?
Filspare (sparsentan) can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Filspare (sparsentan) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
Is Sparsentan FDA-approved?
Yes, the FDA granted accelerated approval to Sparsentan on February 17, 2023.
What Category is Sparsentan?
Sparsentan is classified as a dual endothelin and angiotensin II receptor antagonist.
What is the Brand Name of Filspari?
Sparsentan is marketed under the brand name Filspari and is used to treat primary immunoglobulin A nephropathy.
Can I Take FILSPARI if I’m Pregnant or Planning to Become Pregnant?
No, FILSPARI is contraindicated during pregnancy due to the risk of fetal harm. If you are able to become pregnant, you must use effective contraception before, during, and for one month after stopping FILSPARI. Pregnancy tests are also required before and during treatment.
What are the Main Safety Concerns with FILSPARI?
The main safety concerns with FILSPARI include hepatotoxicity (liver damage) and embryo-fetal toxicity (potential harm to a developing fetus). These risks require careful monitoring, and FILSPARI is only available through a restricted program due to these concerns.
Is it safe to buy FILSPARI online in India?
FILSPARI can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
